DNA-Encoded Libraries
A Small-Molecule Lead-Generation Technology with Expanding Possibilities
4/21/2027 - April 22, 2027 ALL TIMES PDT
Over the past decade DNA-encoded libraries (DEL) have become a core component of pharmaceutical companies’ hit-finding campaigns for new therapeutics. DEL technology is also moving beyond traditional drug lead generation and making its mark in all facets of small-molecule drug discovery, even in peptide discovery. Why is DEL becoming indelible? Join us at CHI's 9th Annual DNA-Encoded Libraries conference to discuss with pioneers and more recent practitioners in the DEL field, the latest DEL successes, newer applications and "nitty-gritty" DELT innovations.
Preliminary Agenda

DEL CASE STUDIES: COVALENT APPLICATIONS & MORE

Covalent Methods in DNA-Encoded Library (DEL) Drug Discovery

Photo of Elizabeth D'ambrosio, PhD, Investigator, DNA-Encoded Library Technology, GlaxoSmithKline , Investigator , DNA-Encoded Library Technology , GlaxoSmithKline
Elizabeth D'ambrosio, PhD, Investigator, DNA-Encoded Library Technology, GlaxoSmithKline , Investigator , DNA-Encoded Library Technology , GlaxoSmithKline

Many of the most relevant therapeutic proteins have not been successfully targeted with traditional small molecules. At GSK we combine DNA Encoded Library technology (DEL) with unique covalent library design, screening and hit calling to target reactive residues on challenging proteins. Our covalent strategies enable ID of reactive pockets and prioritization of molecules with unique MoA. These screens serve to expand small-molecule discovery toward higher therapeutic impact across a range of modalities.

Progression of a Selective BCL2-A1 Inhibitor Identified from a DNA-Encoded Library (DEL) Screen

Photo of Kelly Craft, PhD, Senior Scientist I, Discovery Research, AbbVie Inc. , Senior Scientist I , Discovery Research , AbbVie Inc
Kelly Craft, PhD, Senior Scientist I, Discovery Research, AbbVie Inc. , Senior Scientist I , Discovery Research , AbbVie Inc

BCL2-A1, a member of the BCL-2 anti-apoptotic protein family, is overexpressed in several hematologic malignancies and solid tumors. To identify a novel inhibitor of BCL2-A1, we initiated a DEL screen. This screen identified a promising molecular scaffold featuring a unique but ultimately intractable reversible covalent bond with a buried lysine. Leveraging early covalent fragment-type mass spectrometry-based assays, we developed a new covalent lead that irreversibly engages a critical cysteine.

DNA-Encoded Library Screening Enables the Discovery of an Ebola Virus Entry Inhibitor

Photo of Srinivas Chamakuri, PhD, Assistant Professor, Pathology & Immunology, Baylor College of Medicine , Asst Prof , Pathology & Immunology , Baylor College of Medicine
Srinivas Chamakuri, PhD, Assistant Professor, Pathology & Immunology, Baylor College of Medicine , Asst Prof , Pathology & Immunology , Baylor College of Medicine

Ebola virus (EBOV) causes recurrent, high-fatality outbreaks, and its glycoprotein (GP) is a key mediator of viral entry. DNA-encoded chemical libraries screening against EBOV GP identified MWAC-3634, which binds GP with high affinity, potently neutralizes infection, with no detectable cytotoxicity and favorable pharmacokinetics in mice. Cryo-EM revealed binding to a cavity at the GP1/GP2 interface. Notably, MWAC-3634 protected mice against lethal EBOV challenge, significantly improving survival.

Uncovering Novel Allosteric Sites on WRN Helicase through Collaborative DEL and Fragment-Based Approaches

Photo of Sriram Tyagarajan, Associate Principal Scientist, Discovery Chemistry, Merck Sharp & Dohme LLC , Associate Principal Scientist , Discovery Chemistry , Merck Sharp & Dohme LLC
Sriram Tyagarajan, Associate Principal Scientist, Discovery Chemistry, Merck Sharp & Dohme LLC , Associate Principal Scientist , Discovery Chemistry , Merck Sharp & Dohme LLC

Integrating complementary discovery approaches offers new opportunities to target Werner syndrome helicase (WRN), a promising therapeutic target for certain cancers. This presentation showcases how close collaboration between DNA-encoded library (DEL) and fragment-based lead discovery (FBLD) teams enabled the identification of novel allosteric pockets in WRN and subsequent hit optimization. We will highlight integrated workflows, illustrating how the convergence of DEL and FBLD can inform hit prioritization and optimization.

DEL & MOLECULAR GLUES (DEGRADING AND NON-DEGRADING)

Non-Degradative Protein Modulation with Rapamycin-Inspired Molecular Glue DELs

Photo of Sam Y. Hong, PhD, Senior Director, Platform, Rapafusyn Pharmaceuticals , Sr Dir Platform , Platform , Rapafusyn Pharmaceuticals
Sam Y. Hong, PhD, Senior Director, Platform, Rapafusyn Pharmaceuticals , Sr Dir Platform , Platform , Rapafusyn Pharmaceuticals

Rapafusyn's RapaGlue platform is a DNA-encoded library (DEL) of more than 12 billion non-degrading, macrocyclic molecular glues (MGs). Inspired by rapamycin and FK506, these glues induce new protein-protein interactions between intracellular FKBP12 and a target protein. The platform has a 90% hit rate against challenging targets. We will discuss the concepts and design behind this success, which opens a route to cytosolic enzymes, PPIs, and transmembrane targets.

Discovery of Molecular Glues from an FKBP12-Focused DNA-Encoded Library

Photo of Trevor A. Zandi, PhD, Associate Research Scientist, Craig Crews Lab, Yale University , Associate Research Scientist , Craig Crews Lab , Yale University
Trevor A. Zandi, PhD, Associate Research Scientist, Craig Crews Lab, Yale University , Associate Research Scientist , Craig Crews Lab , Yale University

Molecular glues that form inhibitory ternary complexes such as rapamycin and daraxonrasib have displayed remarkable clinical activity. However, the systematic discovery of molecular glues has been limited. We constructed and screened a multi-million compound DEL, biased to bind and resurface FKBP12, against 25 purified proteins. Hits were validated in biophysical and cellular assays with two distinct targets. Structural data demonstrated mimicry of N-butyryl-lysine histone by an FKBP12/BRD9-binding molecular glue.

DEL Applications to Molecular Glue Discovery

Photo of Lucas Mastromatteo, Senior Scientist, Data Science, GSK , Data Scientist , GSK
Lucas Mastromatteo, Senior Scientist, Data Science, GSK , Data Scientist , GSK

The Encoded Technologies team at GSK uses DNA-Encoded Library (DEL) experiments to simultaneously screen millions of compounds for molecular glues. In this talk, we will outline the experimental workflow, starting with design and ending with statistically-identifying glues. Each DEL experiment is repeated three times, adding confidence to our scoring metrics. Glues are statistically identified based on the relative frequences of each compound between glue, target-alone, and control conditions.

DEL & E3 Ligase Discovery Case Studies

Photo of Christopher B. Phelps, PhD, Vice President and Head, Early Discovery, Nurix Therapeutics, Inc. , VP & Head Early Drug Discovery , Early Drug Discovery , Nurix Therapeutics Inc
Christopher B. Phelps, PhD, Vice President and Head, Early Discovery, Nurix Therapeutics, Inc. , VP & Head Early Drug Discovery , Early Drug Discovery , Nurix Therapeutics Inc

DEL INNOVATIONS

Magnetic Automation in Affinity and OBOC DEL Synthesis and Cellular Screening

Photo of Brian M. Paegel, PhD, Professor, Pharmaceuticals Sciences, University of California, Irvine , Professor , Pharmaceuticals Sciences , University of California, Irvine
Brian M. Paegel, PhD, Professor, Pharmaceuticals Sciences, University of California, Irvine , Professor , Pharmaceuticals Sciences , University of California, Irvine

Magnetic microparticle technology revolutionized genomic sample preparation automation; we are now leveraging these capabilities for automating the complex processes of DEL synthesis and cellular screening. Topics will include anion exchange on-DNA chemical synthesis technology development, magnetic microparticle engineering for multiplexed synthesis and bioactivity detection, and deployment of these technologies in whole-cell activity-based screening.

Building the Next Generation of DEL Datasets for AI

Photo of Timothy L. Foley, PhD, Senior Principal Scientist & Lab Head, DNA Encoded Library Selection & Pharmacology, Pfizer Global R&D Groton Labs , Lab Head, Associate Research Fellow , DNA Encoded Library Selection & Pharmacology , Pfizer Global R&D Groton Labs
Timothy L. Foley, PhD, Senior Principal Scientist & Lab Head, DNA Encoded Library Selection & Pharmacology, Pfizer Global R&D Groton Labs , Lab Head, Associate Research Fellow , DNA Encoded Library Selection & Pharmacology , Pfizer Global R&D Groton Labs

PLENARY SESSIONS

PLENARY KEYNOTE

PLENARY KEYNOTE

Photo of Gwenn Hansen, PhD, CSO, Nurix Therapeutics, Inc. , Chief Scientific Officer , Research , Nurix Therapeutics Inc
Gwenn Hansen, PhD, CSO, Nurix Therapeutics, Inc. , Chief Scientific Officer , Research , Nurix Therapeutics Inc

PLENARY PANEL: INSIGHTS FROM VENTURE CAPITALISTS

Panel Moderator:

PANEL DISCUSSION:
VC Insights on Drug Discovery Trends

Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation , Chief Innovation Officer , Frontier Medicines Corporation

Panelists:

James Edwards, PhD, Venture Partner, Samsara BioCapital , Venture Partner , Samsara BioCapital

Jamie Kasuboski, PhD, Partner, Luma Group , Partner , Luma Group

KT Moortgat, PhD, Managing Partner & Founder, Dalena Capital , Managing Partner & Founder , Dalena Capital

Sonia Setayesh, PhD, Partner, Civilization Ventures , Partner , Civilization Ventures

Chris Smith, PhD, CSO Partner Team, Curie.Bio , VP CSO Partner Team , Drug Discovery , Curie.Bio

Daniella Tedesco, Partner & Co-Founder, NextRound Philanthrophy , Co-Founder , NextRound Philanthrophy


For more details on the conference, please contact:
Anjani Shah, PhD
Senior Conference Director
Cambridge Healthtech Institute
(+1) 781-247-6252
Email: ashah@healthtech.com

For sponsorship information, please contact:
Kristin Skahan
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431
Email: kskahan@healthtech.com


Register Early for Maximum Savings

APRIL 19

Covalent & Induced Proximity-Based Therapies

RNA-Modulating Small Molecule Drugs

Generative AI for Drug Discovery

training seminars

View In-Person Short Courses

APRIL 20 - 21

Degraders & Molecular Glues - Part 1

Small Molecule Discovery Technologies

AI/ML for Early Drug Discovery - Part 1

Linker & Conjugation Chemistries

Peptides

APRIL 21 - 22

Degraders & Molecular Glues - Part 2

Protein-Protein Interactions / Difficult Targets

AI/ML for Early Drug Discovery - Part 2

DNA-Encoded Libraries

GLP1 & Oral Peptides


Drug Discovery Chemsitry Europe

View All Sponsors

View All Media Partners